Full Text
PND45 OCRELIZUMAB IS A COST-EFFECTIVE OPTION FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN IRAN

Abstract

Authors

N. Ayati M.A. Sahraian S. Taheri S. Nikfar

Back to Volume 22, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×